Anavex Soars on Biogen Agreement
Shares of Anavex Life Sciences soared on Wednesday following a material transfer agreement with Biogen.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 195
Red-Hot Biotechs Highlight Jefferies Top Stocks to Buy This Week
In a Jefferies research report, the top growth stock picks for this week are littered with outstanding biotech companies that could be poised for some big moves.
Aetna to Give Away iPhones
Health insurance giant Aetna will start to give away iPhones, iPads and Apple Watches as part of an experiment. But will people use them for health reasons?
Tabula Rasa Healthcare Updates Expected IPO Pricing
Tabula Rasa Healthcare intends to price more than 4 million shares in the range of $13 to $15 per share in an initial public offering valued up to $74 million.
Fulgent Genetics Announces Potential Pricing for IPO
Fulgent Genetics expects to offer more than 4 million shares in an expected price range of $12 to $14 per share in an initial public offering valued up to about $74 million.
Short Sellers Increase Bets in Major Biotechs
The September 15 short interest data have been compared with the previous report, and short interest moves were upward across most of these selected biotech stocks.
Major Pharma Continues to See Rising Tide in Short Interest
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Pfizer Decides Against the Split
Pfizer shares traded down marginally Monday morning after the company announced that it will abandon its plan to split into two companies.
New Crohn’s Disease Drug Approved by FDA
A unit of Johnson & Johnson has announced that the FDA has approved its Stelara for the treatment of moderately to severely active Crohn's disease.
4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate
24/7 Wall St. has picked out some of the major companies in the health care sector that are moving ahead of the first presidential debate and added in some color for each.
How Much Will Consumers Save on New Humira Biosimilar?
In a time when government wrangling about drug prices is more than commonplace, news of a biosimilar for the mega-blockbuster Humira being approved took the backseat to many other things.
6 Biotech and Biohealth Analyst Picks for 50% to 150% Upside
The week of September 23 brought numerous analyst upgrades and downgrades in the biotech and biohealth space.
Could Puma Biotech Double After This FDA Approval?
Puma Biotechnology posted strong gains over the course of this past week, which began with some positive news from the FDA and continued with a huge analyst call.
Endo Shuffles the Deck With New CEO Appointment
Shares of Endo International saw a handy gain in Friday’s session after the company named its new president and chief executive officer.
Why Key Analyst Sees Puma Biotech Practically Doubling
Puma Biotechnology Inc. (NYSE: PBYI) has made solid gains over the course of this week, starting with some positive news from the U.S. Food and Drug Administration (FDA), but now shares are being pushed…